will be determined by the genetics of the SARS-CoV-2 virus itself. The prospects for success in defeating the pandemic in 2021 are therefore uncertain.

SARS CoV-2 Task Force: As we have long maintained, the direction taken by the pandemic will be determined by the genetics of the SARS CoV-2 virus itself. The prospects for success in defeating the pandemic in 2021 are therefore uncertain.

Dramatic development in long-term effects from Covid-19 – Individual recommendations on vaccination for Dr. Hess premium clients.

We have been predicting for some time now that SARS CoV-2 would mutate and evolve. From the variants that have since emerged – in particular B.1.1.7. and 501Y.V2 – it is clear that central monitoring of new variants as they arise, similar to that for influenza viruses, has a vital role to play in ensuring better management of the pandemic. It is also important for us in the work we do advising our clients on vaccination.

... following further mutations in the SARS-CoV-2 virus – Dr. Hess reserves judgment on vaccination.

The eyes of the entire scientific world are currently fixed on two countries: on the one hand, Israel, which has achieved the highest per capita vaccination rates and could therefore provide valuable lessons in terms of vaccine rollout, effectiveness, infectivity and herd immunity; and on the other, Brazil, specifically because of the SARS CoV-2 gene variants discovered there, which have led the British government to impose entry bans from the South American continent and from Portugal.

Doctor Hess introduces infection and vaccination log for Premium Clients.

This last year has gone by surprisingly fast for us, and it seems like only yesterday that we were putting our team together. Almost six weeks before the World Health Organization declared the pandemic, the data we had already received from Asia prompted us to react at a relatively early stage. It was a very busy time for us, during which we learned a lot. Looking back at all of our communications with you during these past 12 months, we have published around 100 Keynotes and at least as many podcasts. They are still all available online as well as on our app. Somewhat to our surprise, none of these communications has turned out to be wrong in terms of content. We have no regrets as to the information we have published here, because we pride ourselves on taking a very clear approach and see ourselves as a filter to minimize the spread of “fake news”.

Right from the start, SARS CoV-2 has measured up to the two main criteria of a model pandemic virus: it spreads easily and kills only a small percentage of those infected. However, new mutant forms have produced a new twist in the plot. It comes as no surprise to us that the goalposts have been moved in favor of the virus.

We have been monitoring tocilizumab for some time now and have already reported on its potential in previous Keynotes. We are of the opinion that it could, under certain circumstances, be used in the treatment of Covid patients.

... of vaccination are minimal to zero.

This internal study involved Dr Robert Hess Premium clients who have subscribed to our Covid-19 Immunization Program since April 2020, who have a Covid-19 Risk Factor of <0.7 and a Cytokine Risk Factor of <0.6, and who have been fully vaccinated with both a first and a second dose. In this internal study, which covered an observation period of approximately eight weeks after vaccination, retests were performed within the scope of our Covid-19 Immunization Program, in which zero to minimal improvement in immune response was detected. The benefits that were noted were in the area of antibodies. In some cases, however, we actually observed deterioration of the interferon system during the study period.

... vaccines and optimization of the immune system is becoming an increasingly uphill challenge.

Dr Robert Hess SARS-CoV-2 Task Force was set up in January 2020 with the aim of providing his Premium clients with the best possible service during the current pandemic by critically evaluating information on SARS-CoV-2, filtering out the irrelevant and/or misleading and communicating the results. It is a job that has become increasingly difficult.

The alpha version of this monitoring program will be applied immediately to all retests for Premium clients at no extra charge.

New strategy emphasis for Dr. Hess clients group in 2022.

Dr Robert Hess considers that the likelihood of a major vaccine campaign bringing the pandemic to an end this summer is diminishing. With this long-term scenario in prospect, we at the Salvagene Group have had a strategic rethink, not least because we have been allocating so much of our resources to SARS-CoV-2 research over the past twelve months. We now intend to significantly expand capacity in our core expertise, namely cancer prevention, to avoid a situation where this priority is repeatedly pushed to one side. We have to work on the assumption that the SARS-CoV-2 virus will keep us occupied for a long time to come. To meet the challenge, we will be reorganizing and significantly expanding our research capacities.